

*ISSN 1669-5402 (Print)*

*ISSN 1669-5410 (Online)*



*Physiological  
Mini-  
Reviews*

*Edited by the Argentine Physiological Society.*

*Vol. 1, N° 9, April 2006.*

<http://www.mini.reviews.safisiol.org.ar>

# Physiological Mini-Reviews

[ISSN 1669-5402 (Print); ISSN 1669-5410 (Online)]

Edited by the **Argentine Physiological Society**

Journal address: Sociedad Argentina de Fisiología, Universidad Favaloro, Solís 453 (1078),  
Ciudad de Buenos Aires Argentina.  
Tel.-Fax: (54) (0)11 43781151  
<http://www.mini.reviews.safisiol.org.ar>

---

*Physiological Mini-Reviews* is a scientific journal, publishing brief reviews on "hot" topics in Physiology. The scope is quite broad, going from "Molecular Physiology" to "Integrated Physiological Systems". As indicated by our title it is not our intention to publish exhaustive and complete reviews. We ask to the authors concise and updated descriptions of the "state of the art" in a specific topic. Innovative and thought-provoking ideas are welcome.

---

## **Editorial Board:**

Eduardo Arzt, Buenos Aires, Argentina.  
Oscar Candia, New York, United States.  
Daniel Cardinali, Buenos Aires, Argentina.  
Hugo Carrer, Córdoba, Argentina.  
Marcelino Cerejido, México City, México.  
Horacio Cingolani, La Plata, Argentina.

Adolfo De Bold, Ottawa, Canada.  
Osvaldo Delbono, Salem, United States.  
Cecilia Hidalgo, Santiago, Chile.  
Carlos Libertun, Buenos Aires, Argentina.  
Gerhard Malnic, Sao Paulo, Brasil.  
Raúl Marinelli, Rosario, Argentina.  
Juan Saavedra, Bethesda, United States.  
David Sabatini, New York, United States.

**Editor in Chief:** Mario Parisi.

---

**Annual suscriptions rates** are (see the electronic version for payment instructions):

- a) Printed (Institutions): 120 U\$\$ (Air mail.)
  - b) Printed (Individuals): 100 U\$\$ (Air mail. Including Safis Annual fee.)
  - c) Electronic (Individuals-.PDF): 30 U\$\$ (Including Safis Annual fee.)
  - d) Electronic (Institutions-.PDF): 50 U\$\$
- 

## **Preparation and Submission of manuscripts:**

"Physiological Mini-Reviews" will have a maximum of 2500 words, 30 references and 4 figures. Material will be addressed to scientific people in general but not restricted to specialist of the field. For citations in the text and reference list see Cerejido et al. Vol 1, N° 1. Final format will be given at the Editorial Office. Most contributions will be invited ones, but spontaneous presentations are welcome. Send your manuscript in Word format (.doc) to:  
[mini-reviews@safisiol.org.ar](mailto:mini-reviews@safisiol.org.ar)

---

## **Advertising:**

For details, rates and specifications contact the Managing Editor at the Journal address e-mail:  
[mini-reviews@safisiol.org.ar](mailto:mini-reviews@safisiol.org.ar)

---

The "Sociedad Argentina de Fisiología" is a registered non-profit organization in Argentina.  
(Resol. IGJ 763-04)

---

## Discovery of Hypothalamic Hormones Controlling Pituitary Function.

**Samuel M. McCann MD**

**Emeritus Professor Pennington Biomedical Research Center,  
LSU, Baton Rouge, LA, USA.  
([smmccann2003@yahoo.com](mailto:smmccann2003@yahoo.com))**

A means by which the brain could control the anterior pituitary gland was discovered by B. A. Houssay *et al.* (1933) (1). In the living toad they found that portal vessels drained blood from a primary capillary plexus in the median eminence (ME) down the pituitary stalk to the sinusoids in the anterior pituitary gland. Popa and Fielding (1) found these vessels in dead animals but believed that the blood flow was upward from the pituitary to the median eminence, a conclusion also reached in the living rabbit by G. W. Harris (1). Later with Green (1947) (1), he found that the flow was downward in the living rat. Since the blood pressure in the portal vessels is very low, it is likely that, depending on the conditions, flow can be either upward or downward. Additionally, the short portal vessels carry blood from the neural lobe across the intermediate lobe to the anterior lobe, thus delivering neural lobe hormones directly in high concentrations to the anterior lobe of the gland. This fact has been largely neglected (1).

We hypothesized that the anterior pituitary was controlled by a family of releasing factors, one for each pituitary hormone. The assay animal for these factors would be the rat with ME lesions. Histological examination of the brains of these rats indicated that the supraopticohypophysial tract had been interrupted in the ME, which was itself destroyed. Testing 48 h after lesions yielded a sensitive preparation. Indeed, if these rats had water intake of 100 ml or more 24 h after lesions, they were much to vasopressin but did not respond to non specific stimuli. We used these rats to demonstrate the CRF activity of synthetic lysine vasopressin given to us by Vigneaud (2, 3). He had just received the Nobel Prize for synthesizing this plus oxytocin.

Using this assay, we demonstrated CRH activity of rat and sheep stalk median eminence (SME) extracts. These were contaminated with ACTH and vasopressin and we quantitated their ascorbic acid depleting activity in our assay animals; roughly 80% of the activity was due to CRF (1959) (4). Royce and Sayers obtained similar results.

Our CRF was purified and separated on Sephadex G-25 followed by CMC chromatography (5, 6) from other releasing and inhibiting factors (1959-65). Because it was a much larger peptide (40 aa) than the other releasing factors, it defied structural characterization for many years. As late as the late 60's, the President of the American Endocrine Society drew a diagram of the hypophysial-adrenal axis leaving out the hypothalamus and CRF. Later we found that vasopressin potentiates the action of CRF on the pituitary (7).

Evidence that oxytocin might be a prolactin releasing factor was provided by Benson and Foley (1959). We confirmed their finding that oxytocin delayed the histological involution of mammary glands of rats from which the litter had been removed. Much later we obtained evidence for a physiological role of oxytocin in control of prolactin secretion (8).

Reflection made it seem odd that oxytocin, one of the three most abundant peptides in the body, the others being vasopressin and atrial natriuretic peptide, would have so little

function. As I was flying down to Rio de Janeiro, this obvious idea occurred to me. Furthermore, I guessed that it was involved in cardiovascular system function. When I arrived to the office of Jose Antunes Rodrigues, one of my long term collaborators, his assistant jumped at the idea and lo and behold oxytocin has a physiologically significant role in physiology of the cardiovascular system to decrease rate and force of contraction of the heart and to dilate blood vessels (1997) (9). It is present in the heart and blood vessels and plays a role in development of the circulation. Oxytocin can convert stem cells into a sheet of synchronously beating cardiomyocytes (2002) (10). These studies complemented our studies of the role of ANP in the cardiovascular system and the body fluid homeostasis (1997) (11).

I felt that there should be both an FSHRF and a LHRH to control secretion of FSH and LH, respectively from the anterior pituitary. What we needed was an assay animal. Since the gonads are steroid-secreting glands like the adrenal, I hypothesized that LH might cause a depletion of ascorbic acid from the testis or from the corpus luteum obtained from pseudopregnant rats. I found little if any effect. That year (1958), the Federation Meeting was held in Philadelphia a stone's throw from my office. Amazingly, Al Parlow presented the assay for LH in young pregnant mares' serum (PMS) and human chorionic growth hormone (HCG) - injected female rats. I was amazed and immediately set out to verify his results. I also injected an 0.1 N HCl extract of rat stalk median eminences, the exact method used to extract CRF.

There was a dose-related effect of SME extract to deplete ovarian ascorbic acid and similar extracts from cerebral cortex had no effect. There was no effect of epinephrine, norepinephrine, serotonin or substance P.

I was going to the International Congress of Physiology in Buenos Aires in 1959 and had planned to give the results. Instead, after meeting Houssay and Leloir, the first a Nobel Laureate, and the second as stated by Houssay to become one, I met Samuel Taleisnik (director of the Institute in Cordoba), who was to join me in Philadelphia on the recommendation of Houssay. We took the night train to Cordoba. I asked him if he could do hypophysectomy in baby rats. He said he could. I showed him the data and told him that he'd be doing hypophysectomy in Philadelphia. He came and was on 9 papers in 1 year. We ruled out LH as a factor in the ascorbic acid depletion and published the first paper on LH-RF (12). I asked Taleisnik to stay and he said he couldn't because he was director of the Institute. After he left I showed that if you inject hypothalamic extract iv into ovariectomized, estrogen primed rats, blood LH increases. Also, LH-RF was a peptide based on enzymatic degradation studies.


At this time (1963), Masao Igarashi came from Japan. He brought with him a new more sensitive assay for FSH, the mouse uterine weight augmentation assay. The Steelman-Pohley assay was too insensitive for our studies. I told him that after a few improvements, his assay would be suitable and we would discover the FSH-RF. He presented the discovery of FSH-RF at the Endocrine Meeting in Atlantic City in 1963 and we published in full shortly after in 1964 (13). I had no experience and had no luck trying to recruit peptide chemists. Gel filtration on Shephadex G-25 appeared to be an ideal technique to separate small peptides. Therefore, I set up a small column of Shephadex G-25 and collected the fractions over night in the cold room. The peaks of FSH-RF and LHRH overlapped completely.

Fortunately, Anand Dhariwal arrived at this point. He set up a tall skinny Shephadex G-25 column. There was a clear separation of the FSH-RF eluting just prior to the LHRH

(1965). Schally confirmed these results using the FSH assay, shown to him on the way back to Japan by Igarashi. Now, Schally doesn't quote his own work which is doing severe damage to this field! Not only did we separate FSH-RF from LHRH but also from other releasing factors (5, 14).

We believe FSH-RF is lamprey GnRH III. Antibodies against it block the action of FSH-RF. It is localized to the dorsomedial preoptic area, an area that controls FSH release and not LH release (15). Mass spectroscopy of purified FSH-releasing hypothalamic extracts reveals a peptide with its molecular weight (unpublished data). Biotinylated L-GnRH III binds selectively to FSH gonadotropes, whereas biotinylated LHRH binds selectively to LH gonadotropes (15). FSH-RF mediates separate pulses of FSH (15).

It occurred to me that since mating behavior occurred in the rat shortly after LH was released to induce ovulation, that LHRH might induce mating behavior. I had no experience with mating studies. Therefore I hired Bob Moss, an electrophysiologist who obtained his PhD for sex behavior studies in rats. I told him my idea and said that when the structure of LHRH broke we would test it for mating behavior. It wasn't long until the structure was elucidated in Schally's laboratory by Matsuo. I called Schally and asked if we could have some synthetic LHRH. He said it already was being provided to people in 40 labs around the world. Fortunately, we got it quite soon without his help. I gave some to Moss and asked him to try it. Several months went by. Finally I called him in. He said he was sure it wouldn't work, so he hadn't tried it. I said I think it will work, try a high dose in ovariectomized-estradiol-primed rats. If it doesn't work you'll be finished with it, but if it works you'll be working with it for the rest of your life. It worked like a charm (16) and he worked on it until his premature death. (Fig.1)




**Fig. 1.** Parasagittal section of preoptic and hypothalamic region of the rat brain illustrating the distribution of FSHRH and LHRH neurons. Abbreviations: POA = preoptic area, AC = anterior commissure, OC = optic chiasm, 3V = third ventricle, ME = median eminence, MB = mammillary body, M Brain = midbrain, AP = anterior pituitary, IL = intermediate lobe, NL = neuronal lobe.

LHRH neurons arise in the medial preoptic area (MPOA) and project to the mid and caudal ME to release LHRH into the portal vessels for stimulation predominantly of LH and to a lesser extent of FSH.

FSH-RH neurons arise also in the MPOA slightly rostral to the LHRH neurons and project to the rostral ME. They release FSH-RH into the portal vessels to stimulate predominantly FSH and to a lesser extent LH. In the ventral MPOA, there are some neurons that contain both, FSH-RH and LHRH. The axons of another population of LHRH neurons descend to the midbrain central grey. The perikarya of all these neurons is activated by NO and cGMP. This last population mediates sex behaviour.

We had earlier studied the effect of cAMP on hypothalamic pituitary function and since cGMP had no known functions and was a major cyclic nucleotide, we wondered if cGMP might have a role to play. Indeed, we found that cGMP mediated the action of GnRH's on the pituitary (17, 18). Now we know that NO stimulates gonadotropin release by cGMP (15). (**Fig. 2**)



**Fig. 2.** Schematic diagram illustrating the mechanism of the gonadotropin-releasing action of FSHRH, LHRH and leptin, N = nucleus. The principal pathway is via NO, cGMP and PKG, but  $Ca^{2+}$  may have an independent action.

FSH gonadotropes have FSHRH receptors in their cell surface. FSHRH interacts with FSHRH receptors to increase intracellular  $Ca^{2+}$  that combines with calmodulin to activate NOS. The NO generated activates guanylyl cyclase which converts GTP to GMP that activates PKG leading to extrusion of FSH granules from the cell. LHRH acts analogously to release predominantly LH. If the cell expresses both receptors it will respond to both releasing factors. Leptin reaching the adenohypophysis acts on its own receptors to cause release of LH and to a lesser extent of FSH by the same pathway just described.

Lad Krulich from Prague had been working with us for some years. We decided to see if our hypothalamic extracts would stimulate GH release from the pituitary. He would inject the stalk median eminence extract iv and then measure the depletion of GH from the

pituitary assayed by widening of the tibial epiphyseal plate of hypophysectomized rats. He quickly found a hypothalamic GH-RF and then switched to a better assay studying the effect of purified hypothalamic extracts on GH release from rat pituitaries *in vitro*. With Dhariwal he purified the GIF by gel filtration and CMC, separating it from the others releasing factors (19, 20).

Several years later Guillemin's group purified this peptide and synthesized it, renaming it somatostatin (1972). In the original version of this manuscript he didn't mention our work. The referees complained and it was changed to say that we had found it in crude extracts. That was a lie because crude extracts had a GH-releasing action. Somatostatin is a tetradecapeptide that has never been shown to have growth inhibitory action. The name is a misnomer but still it is used.

We purified and separated all of these peptides that we worked on one from another. Gel filtration on Sephadex G-25 separated them more or less according to molecular weight. The larger the peptide, the earlier its elution. Therefore, the largest, CRF eluted followed by GRF, GIF, FSH-RF, LHRH and vasopressin (5). We discovered a peptidic PIF but did not pursue this further since dopamine turned out to be a powerful PIF (15).

By cutting frozen section horizontally and frontally we localized the various RF's by bioassays in the preoptic and hypothalamic areas (21), results later confirmed by immunocytochemistry. Martini postulated that pituitary hormones would have a short loop negative feedback and that hypothalamic hormones would have an ultrashort negative feedback. We have found many examples of these actions (15), which probably act for all transmitters.

In the ovariectomized-estrogen-primed female rat the negative feedback of estrogen to decrease LHRH release is reversed and becomes positive to increase LHRH release by NO that stimulates LH release from the adenohypophysis but also acts in the brain stem to augment mating behavior by inducing lordosis. It also activates pelvic neurons which act by NO released in the corpora cavernosa penis to cause penile erection (15). This is but one example of the ubiquitous role of NO as a synaptic transmitter.

Acetyl choline, dopamine, NE, serotonin, glutamic acid, GABA and NO interact in complex ways to participate in hypothalamic control of releasing and inhibiting hormone release (15).

In 1966, we published our first study on neuroimmunomodulation which was a comparison of the effect of environmental and preoptic heating with that of fever induced by purified LPS that increased cortisol release in dogs (22). Twenty years later we determined the ability of proinflammatory cytokines to induce the pattern of pituitary hormone release during infection (23). With Valeria Rettori and Les Dees we showed with immunocytochemistry that there were some neurons containing IL-1  $\alpha$  among the dorsomedial preoptic temperature sensitive neurons and that they were dramatically induced by LPS (24). Ma Li Wong showed that IL-1  $\beta$  mRNA could be induced in neurons in the paraventricular and arcuate nucleus by LPS (25).

With Omid Khoram and Jim Lipton we showed that  $\alpha$ MSH had an antipyretic effect on LPS-induced fever. Indeed  $\alpha$  MSH is an anti-inflammatory cytokine (26).

With Tibor Wenger and Valeria Rettori we studied the hypothalamic action of  $\delta$ 9-tetrahydrocannabinol, the active ingredient of marijuana (27). We believed that there must be an endogenous cannabinoid with appropriate receptors. We were pleased to see the

discovery of an endogenous ligand, anandamide (AEA) with two receptors, Cb1r and Cb2r. With Valeria Rettori and her group we have carried out extensive studies indicating that many drugs act by endocannabinoids activating Cb1r or Cb2r. For example the action of alcohol to suppress LHRH release can be blocked by a Cb1r blocker (28).

With Ramirez, we found that immature rats were excruciatingly sensitive to the negative feedback of gonadal steroids. After puberty the sensitivity declined several fold (29). Some time later Coleman discovered dwarfed obese sterile mice. The defect was in a single gene named obese (Ob). Only homozygous Ob-Ob mice showed the defects. Coleman parabiosed a thin mouse to an Ob-Ob mouse resulting in the fat mouse becoming thin. It was hypothesized that there was a hormonal defect in the fat mouse. People looked in vain for the hormone in the blood and in the urine. Nothing happened until Zhang and Friedmann by positional cloning obtained its structure, making possible the synthesis of leptin.

With Wen Yu we determined that leptin acted in the basal tuberal region to release LHRH by NO. It also acted on the anterior pituitary to stimulate LH and to a lesser extent FSH with the same potency as LHRH. With Claudio Mastronardi we discovered that leptin was present in adipocytes in large amounts and its secretion could be stimulated within 10 min. There was a circadian rhythm of plasma leptin with a peak at 1.30 AM and a nadir at 7.30 AM in man and rats. Finally, plasma leptin throughout the 24h paralleled that of NO<sub>2</sub>-NO<sub>3</sub>, suggesting that leptin stimulated NO. Indeed, leptin stimulated NO<sub>2</sub>-NO<sub>3</sub> and TNF- $\alpha$  release from incubated epididymal fat pads (30). Finally, Julio Licinio demonstrated that Ob-Ob humans failed to go into puberty but that it could be induced by leptin, indicating that leptin is the major inducer of puberty (31).

In conclusion, we must be open to new ideas. One must take time to go over a problem considering all the possibilities for its solution. This is the way to get new ideas. The most important thing for progress is the new idea. Without it progress ceases.

## **REFERENCES**

- 1. McCann SM, Dhariwal APS, Porter JC.** Regulation of the adenohipophysis. *Ann Rev Physiol* 1968; 30: 589-640.
- 2. McCann SM, Fruit A.** Effect of synthetic vasopressin on release of adrenocorticotrophin in rats with hypothalamic lesions. *Proc Soc Exp Biol Med.* 1957; 96(3):566-567.
- 3. McCann SM.** The ACTH-releasing activity of extracts of the posterior lobe of the pituitary in vivo. *Endocrinology* 1957; 60: 664-676.
- 4. McCann SM, Haberland P.** Relative abundance of vasopressin and corticotrophin-releasing factor in neurohypophyseal extracts. *Proc Soc Exp Biol Med* 1959; 102: 319-325.
- 5. McCann SM and Porter JC.** Hypothalamic pituitary stimulating and inhibiting hormones. *Physiol Rev* 1969; 49: 240-283.
- 6. McCann SM.** Saga of the discovery of releasing and inhibiting hormones 1988. In: People and Ideas in Endocrinology, S. M. McCann (ed.). *Am Physiologic Society*, 1988; pp 41-62.



7. **Yates FE, Russell SM, Dallman MF, Hodge GA, McCann SM, Dhariwal AP.** Potentiation by vasopressin of corticotropin release induced by corticotropin-releasing factor. *Endocrinology* 88(1): 3-15, 197.
8. **Samson WK, Lumpkin MD, McCann SM.** Evidence for a physiological role for oxytocin in the control of prolactin secretion. *Endocrinology* 1986; 119: 554-560.
9. **Antunes Rodrigues J, de Castro M, Elias LL, Valenca MM, McCann SM.** Neuroendocrine control of body fluid metabolism. *Physiol Rev* 2004; 84: 169-208.
10. **Paquin J, Danalache BA, Jankowski M, McCann SM, Gutkowska J.** Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes Proc Natl Acad Sci 2002; 99: 9550-9555.
11. **Antunes Rodrigues J, McCann SM, Samson WK.** Central administration of atrial natriuretic factor inhibits salt intake in the rat. *Endocrinology* 1986; 118: 1726-1729.
12. **McCann SM, Taleisnik S, Friedman HM.** LH-releasing activity in hypothalamic extracts. Proc Soc Exp Biol Med 1960; 104: 432-434.
13. **Igarashi M, McCann SM.** A hypothalamic follicle stimulating hormone releasing factor. *Endocrinology* 1964; 74: 446-452.
14. **Dhariwal APS, Nallar R, Batt M, McCann SM.** Separation of FSH-releasing factor from LH-releasing factor. *Endocrinology* 1965; 76: 290-294.
15. **McCann SM, Karanth S, Mastronardi CA, Dees WL, Childs G, Miller B, Sower S, Yu W. H.** Hypothalamic control of gonadotropin secretion. In: *Progress in Brain Research, Volume 141, Gonadotropin-Releasing Hormone: Molecules and receptors, I. S. Parhar (ed.), Elsevier Science, The Netherlands*, chapter 11, 2002; pp 153-166.
16. **Moss RL, McCann SM.** Induction of mating behavior in rats by luteinizing hormone-releasing factor. *Science* 1973; 181(95):177-179.
17. **Nakano H, Fawcett CP, Kimura F, McCann SM.** Evidence for involvement of cGMP in regulation of gonadotropin release. *Endocrinology* 1978; 103: 1527-1533.
18. **Naor Z, Fawcett CP, McCann SM.** The involvement of CGMP in LHRH stimulated gonadotropin release. *Amm J Physiol* 1978; 235: 586-690.
19. **Krulich L, Dhariwal AP, McCann SM.** Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. *Endocrinology* 1968; 83(4):783-790.
20. **Krulich L, McCann SM.** Effect of GH-releasing factor and GH-inhibiting factor on the release and concentration of GH in pituitaries incubated in vitro. *Endocrinology* 1969; 85(2):319-324.
21. **Wheaton JE, Krulich L, McCann SM.** Localization of LHRH in the preoptic area and hypothalamus of the rat using RIA. *Endocrinology* 1975; 97: 30-38.
22. **Chowers I, Hammel HT, McCann SM.** Comparison of effect of environmental and preoptic cooling on plasma cortisol levels. *Am J Physiol* 1964; 207: 577-582.
23. **McCann SM, Kimura M, Yu WH, Mastronardi CA, Rettori V, Karanth S.** In: *Vitamins and Hormones, Vol 63. G Litwack (ed.). Academic Press, San Diego, 2001; pp 29-62.*

24. **Rettori V, Dees WL, Hiney JK, Lyson K, McCann SM.** An IL-1  $\alpha$ -like neuronal system in the preoptic hypothalamic region and its induction by LPS in concentrations which alter pituitary hormone release. *Neuroimmunomodulation* 1994; 1: 251-258.
25. **Wong ML, Rettori V, Al-Sheklee A, Bongiorno PB, Canteros G, McCann SM, Gold PW, Licinio J.** Inducible NO synthase gene expression in the brain during systemic inflammation. *Nat Med* 1996; 2: 581-584.
26. **Shih ST, Khorram O, Lipton JM, McCann SM.** Central administration of  $\alpha$ -MSH antiserum augments fever in the rabbit. *Am J Physiol* 1986; 250: 803-806.
27. **Wenger T, Rettori V, Snyder GD, Dalterio S, McCann SM.** Effects of delta 9-tetrahydrocannabinol (THC) on the hypothalamic-pituitary control of LH and FSH secretion in adult male rats. *Neuroendocrinology* 1987; 46: 488-493.
28. **Fernandez Solari J, Scorticati C, Mohn C, De Laurentiis A, Billi S, Franchi A, McCann SM, Rettori V.** Alcohol inhibits luteinizing hormone-releasing hormone release by activating the endocannabinoid system. *Proc natl Acad Sci* 2004; 101: 3256-3268.
29. **Ramirez VD, McCann SM.** A comparison of the regulation of luteinizing hormone (LH) secretion in immature and adult rats. *Endocrinology* 1963; 72: 452-464.
30. **McCann SM, Karanth S, Yu WH, Mastronardi CA.** Neuroendocrine regulation of leptin secretion and its role in nitric oxide secretion. In: *Leptin and Reproduction*, ed. Henson and Castracane, Kluwer Academic Plenum Publishers, 2003.
31. **Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O'Kirwan F, Whitby R, Liang L, Cohen P, Bhasin S, Krauss RM, Veldhuis JD, Wagner AJ, DePaoli AM, McCann SM, Wong M.** Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. *Proc Natl Acad Sci* 2004; 101: 4531-4536.

## **XXII CONGRESO LATINOAMERICANO Y 1ER IBERO-AMERICANO DE CIENCIAS FISIOLÓGICAS**

**Organizado por la Sociedad Argentina de Fisiología, por decisión de la Asociación Latinoamericana de Ciencias Fisiológicas (ALACF) y con el auspicio de la Sociedad Española de Ciencias Fisiológicas  
Buenos Aires, 4 al 7 de noviembre de 2006**

Este año tendrá lugar en Buenos Aires el XXII Congreso de la Asociación Latinoamericana de Ciencias Fisiológicas (ALACF). Esta reunión congregará a científicos originarios de América Latina trabajando en sus países de origen, en Estados Unidos, en Europa y alrededor del mundo. Fisiólogos no latinoamericanos de primer nivel son también regularmente invitados. Esta vez la Sociedad Española de Ciencias Fisiológicas se asocia al evento, dándole especial interés y relevancia.

El objetivo central del Congreso es dar, a los fisiólogos trabajando y viviendo en Latinoamérica, la posibilidad de entrar en contacto con referentes en su campo de trabajo. Esto será especialmente cierto esta vez para aquellos radicados en el Cono Sur del continente (Bolivia, Brasil, Chile, Paraguay, Uruguay y Argentina).

### **Comité Científico Internacional**

**José Antunes-Rodrigues (Brasil)**  
**Eduardo Arzt (Argentina)**  
**Carlos Caputo (Venezuela)**  
**Marcelino Cereijido (Méjico)**  
**Horacio Cingolani (Argentina)**  
**Adolfo de Bold (Canada)**  
**Cecilia Hidalgo (Chile)**  
**Gerhard Malnic (Brasil)**  
**Luisa Rocha (Méjico)**  
**Juan Saavedra (USA)**  
**Javier Salazar (España)**  
**Luis Sobrevia (Chile)**  
**Jesus Tresguerres (España)**  
**Ricardo Velluti (Uruguay)**  
**Guillermo Whitembury (Venezuela)**

### **Comité Organizador:**

Valeria Rettori (Chairperson); Mario Parisi (co-chair-person); Cristina Arranz; Liliana Bianciotti; Graciela Cremaschi; Cristina Damasco; Juan Carlos Elverdín; Paula Ford; Alicia Motta; Adriana Torres; Myriam Wald.

### **Comité de Programa:**

Claudia Capurro (Coordinadora); Ana Balaszczuk; Claudia Capurro; Daniel Cardinali; Paula Faillace; Gustavo Mujer; Valeria Rettori; Marcelo Vatta

Inscripciones o consultas: **[www.congreso-alacf.safisiol.org.ar](http://www.congreso-alacf.safisiol.org.ar)**

---

---



Argentine  
Physiological  
Society

---